MX2022016544A - Agentes de union a lair-1 y metodos para su uso. - Google Patents

Agentes de union a lair-1 y metodos para su uso.

Info

Publication number
MX2022016544A
MX2022016544A MX2022016544A MX2022016544A MX2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A
Authority
MX
Mexico
Prior art keywords
binding agents
lair
methods
antibodies
compositions
Prior art date
Application number
MX2022016544A
Other languages
English (en)
Inventor
Yan Wang
Betty Chan Li
Suzanne Christine Crawley
Bin Fan
Lee Benjamin Rivera
James Robert Sissons
Jonathan Sitrin
Xuan Zhao
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of MX2022016544A publication Critical patent/MX2022016544A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a LAIR-1, incluido LAIR-1 humano, así como composiciones que comprenden los agentes de unión, y métodos para su uso. La descripción también proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que comprenden los agentes de unión.
MX2022016544A 2020-06-22 2021-06-21 Agentes de union a lair-1 y metodos para su uso. MX2022016544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042299P 2020-06-22 2020-06-22
US202063122877P 2020-12-08 2020-12-08
PCT/US2021/038251 WO2021262597A2 (en) 2020-06-22 2021-06-21 Lair-1-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022016544A true MX2022016544A (es) 2023-04-05

Family

ID=76959074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016544A MX2022016544A (es) 2020-06-22 2021-06-21 Agentes de union a lair-1 y metodos para su uso.

Country Status (15)

Country Link
US (1) US20220041711A1 (es)
EP (1) EP4168451A2 (es)
JP (1) JP2023532857A (es)
KR (1) KR20230039640A (es)
CN (2) CN116813777A (es)
AU (1) AU2021296168A1 (es)
BR (1) BR112022026284A2 (es)
CA (1) CA3187944A1 (es)
CL (1) CL2022003684A1 (es)
CO (1) CO2022018537A2 (es)
IL (1) IL299245A (es)
MX (1) MX2022016544A (es)
PE (1) PE20230839A1 (es)
TW (1) TW202216768A (es)
WO (1) WO2021262597A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230220076A1 (en) * 2021-12-21 2023-07-13 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023173091A1 (en) * 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
WO2023215829A1 (en) * 2022-05-05 2023-11-09 Amgen Inc. Heteromultimer binding dll3 and cd3
WO2024067864A1 (en) * 2022-09-30 2024-04-04 Shanghai Junshi Biosciences Co., Ltd. Anti-lair1 antibodies and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004850A2 (en) * 2006-03-08 2008-12-24 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
KR101947702B1 (ko) 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
KR102617853B1 (ko) * 2017-01-02 2023-12-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-lair1 항체 및 그의 용도

Also Published As

Publication number Publication date
EP4168451A2 (en) 2023-04-26
PE20230839A1 (es) 2023-05-19
KR20230039640A (ko) 2023-03-21
CN116813777A (zh) 2023-09-29
TW202216768A (zh) 2022-05-01
BR112022026284A2 (pt) 2023-03-07
WO2021262597A9 (en) 2022-06-02
WO2021262597A3 (en) 2022-02-24
IL299245A (en) 2023-02-01
AU2021296168A1 (en) 2023-02-02
CN116209676A (zh) 2023-06-02
JP2023532857A (ja) 2023-08-01
CA3187944A1 (en) 2021-12-30
CL2022003684A1 (es) 2023-07-28
US20220041711A1 (en) 2022-02-10
CO2022018537A2 (es) 2023-03-07
WO2021262597A2 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
PH12020551997A1 (en) Psma binding agents and uses thereof
MY194642A (en) Antibodies binding to cd3
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2022013466A (es) Agentes de union a ilt y metodos para su uso.
CR20200341A (es) Anticuerpos de unión a gprc5d
CR20200465A (es) Agentes anticuerpos anti-cd25
EA202190435A1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3
PH12020500664A1 (en) C3-binding agents and methods of use thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
CR20220256A (es) Anticuerpos que se unen a hla-a2/mage-a4
WO2018169922A3 (en) Chimeric antigen receptors for melanoma and uses thereof
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
CR20210091A (es) Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2022016069A (es) Anticuerpos que se unen a cd3 y cd19.